Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

Arecor Presents Positive Data From Phase I Clinical Trial Of Ultra-Concentrated Ultra-Rapid Acting Insulin At278 In ...

Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for peopl ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

The authors convincingly demonstrate, using a battery of experimental techniques and relying on the mapped whole brain connectome, how the heterogeneity in the responses across individual IPCs occur ...

Diabetics who fly with an insulin pump could find themselves with lower-than-normal blood sugar levels, a new study sa ...

CF is an inherited disorder that causes the mucus in your body to be thick and sticky. It affects many organs and body ...